Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome

Transplantation

Volumn 94, Issue 5, 2012, Pages 486-491

  Shah, Sapna ^a   Harwood, Steven M ^a   Döhler, Bernd ^b   Opelz, Gerhard ^b   Yaqoob, Muhammad M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

IMPDH; Outcome; Polymorphisms; Renal transplantation; SNPs

Indexed keywords

CYCLOSPORIN; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ALLELE; ARTICLE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; ENZYME POLYMORPHISM; FOLLOW UP; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GRAFT SURVIVAL; HUMAN; IMPDH I GENE; IMPDH II GENE; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

BIOLOGICAL SPECIMEN BANKS; GENE FREQUENCY; GENOTYPE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; PHENOTYPE; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866338207     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31825b7654     Document Type: Article

References (23)

1. Allison AC, Hovi T, Watts RW, et al. Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation. Lancet 1975; 2: 1179.
2. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345: 1321.
3. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61: 1029.
4. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225.
5. Kaufman DB, Shapiro R, Lucey MR, et al. Immunosuppression: practice and trends. Am J Transplant 2004; 4(suppl 9): 38.
6. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for denovo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008; 86: 1043.
7. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycopheno-late mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006; 82: 102.
8. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381.
9. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200.
10. Takemoto SK, Pinsky BW, Schnitzler MA, et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant 2007; 7: 2704.
11. Tierce JC, Porterfield-Baxa J, Petrilla AA, et al. Impact of mycophe-nolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 2005; 19: 779.
12. Glander P, Hambach P, Braun KP, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004; 4: 2045.
13. Wang J, Yang JW, Zeevi A, et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 2008; 83: 711.
14. Kagaya H, Miura M, Saito M, et al. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation. Basic Clin Pharmacol Toxicol 2010; 107: 631.
15. Gensburger O, Van Schaik RH, Picard N, et al. Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. Phar-macogenet Genomics 2010; 20: 537.
16. Wang J, Zeevi A, Webber S, et al. A novel variant L263F in human inosine 5¶-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics 2007; 17: 283.
17. Pazik J, Oldak M, Podgorska M, et al. Lymphocyte counts in kidney allograft recipients are associated with IMPDH2 3757T9C gene polymorphism. Transplant Proc 2011; 43: 2943.
18. Sombogaard F, van Schaik RH, Mathot RA, et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T9C polymorphism. Pharmaco-genet Genomics 2009; 19: 626.
19. Grinyo J, Vanrenterghem Y, Nashan B, et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 2008; 21: 879.
20. Winnicki W, Weigel G, Sunder-Plassmann G, et al. An inosine 5¶-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid. Pharmacogenomics J 2010; 10: 70.
21. van Schaik RH, van Agteren M, de Fijter JW, et al. UGT1A9-275T9A/-2152C9T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther 2009; 86: 319.
22. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496.
23. Heinold A, Opelz G, Scherer S, et al. Role of minor histocompatibility antigens in renal transplantation. Am J Transplant 2008; 8: 95.